Peripheral Artery Disease

Angioplasty, or the removal of plaque in arteries, is a short-term solution for a chronic problem in patients with cardiovascular disease. Following the procedure, a bare metal stent (metal tube) is placed to physically keep the vessel from narrowing. Recently, new drug-eluting stents containing either paclitaxel or rapamycin have been approved for treatment of restenosos in the coronary arteries. The drug helps to prevent hardening of the artery in conjunction with the placement of the bare metal stent. Cardio-Pac and Cardio-Doc, microtubule stabilizer taxol based products, are being developed by Chikujee to be used in conjunction with stents to prevent various forms of arterial restenosis. Chikujees’ current research on these taxol based products is focused on coronary and peripheral artery restenosis.

Peripheral Artery Disease
Peripheral artery disease of the lower extremities is common in older adults with significant morbidity. Similar to coronary artery disease, this disorder is typically caused by thickening of the blood vessel wall that limits blood flow to the legs, particularly due to narrowing or closure of the superficial femoral artery. Currently the standard treatment is angioplasty alone. Surgical placement of bare metal stents or tubes within the blood vessel has had limited success, most often due to the tube breaking. Development studies are focusing on the use of Cardio-Pac and Cardio-Doc as site specific treatment, along with angioplasty of the affected blood vessel.

Product Portfolio

Cardio-Pac: Paclitaxel based multifunctional NanoBindi

Cardio-Doc: Docetaxel based multifunctional NanoBindi